Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer

Cancer

Volumn 115, Issue 11, 2009, Pages 2580-2593

  Iwakiri, Shotaro ^a   Mino, Nobuya ^a   Takahashi, Tsuyoshi ^a   Sonobe, Makoto ^a   Nagai, Shinjiro ^a   Okubo, Kenichi ^a   Wada, Hiromi ^a   Date, Hiroshi ^a   Miyahara, Ryo ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Chemokine receptor; CXCR4; CXCR7; Disease free survival; Epidermal growth factor receptor; Nonsmall cell lung cancer; Postoperative metastatic recurrence; Prognosis; Real time quantitative reverse transcriptase polymerase chain reaction

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; CHEMOKINE RECEPTOR CXCR7; EPIDERMAL GROWTH FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DISEASE FREE INTERVAL; EGFR GENE; FEMALE; GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS POTENTIAL; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; RECURRENT CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, CXCR; RECEPTORS, CXCR4; TUMOR MARKERS, BIOLOGICAL;

EID: 66649093881     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24281     Document Type: Article

References (46)

1. Pearson FG. Non-small cell lung cancer: role of surgery for stages I-III. Chest. 1999;116:500S-503S. (Pubitemid 30013168)
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717. (Pubitemid 27260107)
3. Baggiolini M. Chemokines and leukocyte traffic. Nature. 1998;392:565-568.
4. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436-445.
5. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121-127. (Pubitemid 30398626)
6. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
7. Taub DD. Chemokine-leukocyte interactions. The voodoo that they do so well. Cytokine Growth Factor Rev. 1996;7: 355-376.
8. Rollins BJ. Chemokines. Blood. 1997;90:909-928.
9. Kakinuma T, Hwang ST. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol. 2006;79:639-651.
10. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410:50-56. (Pubitemid 32225831)
11. Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 2002;62:7328-7334. (Pubitemid 36025256)
12. Mashino K, Sadanaga N, Yamaguchi H, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 2002; 62:2937-2941. (Pubitemid 34525782)
13. Su L, Zhang J, Xu H, et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res. 2005;11:8273-8280. (Pubitemid 41746937)
14. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Strieter RM. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med. 2003;167: 1676-1686. (Pubitemid 36760683)
15. Miao Z, Luker KE, Summers BC, et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA. 2007;104:15735-15740. (Pubitemid 350035369)
16. Takanami I. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis. Int J Cancer. 2003;105:186-189. (Pubitemid 36505319)
17. Spano JP, Andre F, Morat L, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004;15:613-617. (Pubitemid 38559598)
18. Sonobe M, Manabe T, Wada H, Tanaka F. Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. Br J Cancer. 2005;93:355-363. (Pubitemid 43080038)
19. Sonobe M, Nakagawa M, Takenaka K, et al. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl- MAPK, and on the prognosis of patients with nonsmall cell lung cancer. J Surg Oncol. 2007;95:63-69. (Pubitemid 46122720)
20. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900-5909. (Pubitemid 46300206)
21. Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005;23:8081-8092. (Pubitemid 46657411)
22. Greene FL, Page DL, Fleming ID, et al, eds. American Joint Committee on Cancer Staging Manual. 6th ed. Philadelphia, PA: Springer; 2002.
23. Tanaka F, Otake Y, Nakagawa T, et al. Expression of polysialic acid and STX, a human polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer. Cancer Res. 2000;60:3072-3080. (Pubitemid 30395837)
24. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinibsensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163-1167. (Pubitemid 39100331)
25. Arao T, Fukumoto H, Takeda M, Tamura T, Saijo N, Nishio K. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res. 2004; 64:9101-9104. (Pubitemid 39665524)
26. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9:3625-3634. (Pubitemid 37169227)
27. Uchida H, Iwashita Y, Sasaki A, et al. Chemokine receptor CCR6 as a prognostic factor after hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol. 2006;21:161-168.
28. Klatte T, Seligson DB, Leppert JT, et al. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol. 2008;179:61-66. (Pubitemid 350216740)
29. Jiang YP, Wu XH, Shi B, Wu WX, Yin GR. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol. 2006;103:226-233. (Pubitemid 44374693)
30. Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 2005;11:2561-2567. (Pubitemid 40569454)
31. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005;23:2744-2753. (Pubitemid 46179464)
32. Schimanski CC, Schwald S, Simiantonaki N, et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005;11:1743-1750. (Pubitemid 40471835)
33. Scala S, Ottaiano A, Ascierto PA, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 2005;11:1835-1841. (Pubitemid 40471847)
34. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol. 2007;60:596-599. (Pubitemid 46975211)
35. Burns JM, Summers BC, Wang Y, et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006;203:2201-2213. (Pubitemid 44352240)
36. Choi SH, Mendrola JM, Lemmon MA. EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene. 2007;26:1567-1576. (Pubitemid 46398741)
37. Phillips RJ, Mestas J, Gharaee-Kermani M, et al. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem. 2005;280:22473-22481. (Pubitemid 40827903)
38. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol. 2007;25:5562-5569.
39. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA. 2001;98:13790-13795. (Pubitemid 33115977)
40. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA. 2001;98:13784-13789. (Pubitemid 33115976)
41. Beer DG, Kardia SL, Huang CC, et al. Gene expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8:816-824.
42. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33:49-54. (Pubitemid 36068681)
43. Tomida S, Koshikawa K, Yatabe Y, et al. Gene expressionbased, individualized outcome prediction for surgically treated lung cancer patients. Oncogene. 2004;23:5360-5370. (Pubitemid 39005811)
44. Wang J, Shiozawa Y, Wang J, et al. The role of CXCR7/ RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem. 2008;283:4283-4294.
45. Kawada K, Sonoshita M, Sakashita H, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res. 2004;64:4010-4017. (Pubitemid 38697317)
46. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005;65:967-971. (Pubitemid 40216458)